This means that NVK is expected to become the second lowconcentration atropine eye drops approved in China, bringing new treatment options to hundreds of millions of myopic children in China.
. The breakthrough is not accidental. The certainty of the second domestic atropine being launched is further enhanced.
As a lowconcentration atropine drug specifically targeting the progression of myopia in children and adolescents, NVK's global research and development history has fully demonstrated that its breakthrough in the market is no accident. The drug has undergone multiple clinical trials in many regions around the world, including North America, Europe and China. It is the largest, longest and most comprehensive project in the research of atropine drugs on the market.
It is reported that the simplified new drug application for NVK is based latvia phone number list on the Phase III MiniCHAMP clinical study conducted by Zhaoke Ophthalmology in China.
In August , Zhaoke Ophthalmology completed the oneyear MiniCHAMP trial in China. The trial involved centers and enrolled patients.
Judging from the results of clinical studies, MiniCHAMP successfully achieved its primary efficacy endpoint, achieved statistically and clinically significant differences compared with placebo, and demonstrated strong safety and efficacy as well as high patient tolerance. This shows the clinical application value of NVK in controlling the progression of myopia in children.